Cargando…

Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia

BACKGROUND: Encephalitis with antibodies against N-methyl-D-aspartate receptor (NMDA-R) is classified as an autoimmune disorder with psychotic symptoms, which are frequently dominant. However, it remains unclear how frequently NMDA-R antibodies lead to a condition that mimics psychosis and first-epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Masopust, Jiří, Andrýs, Ctirad, Bažant, Jan, Vyšata, Oldřich, Kuca, Kamil, Vališ, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358648/
https://www.ncbi.nlm.nih.gov/pubmed/25834440
http://dx.doi.org/10.2147/NDT.S80746
_version_ 1782361273940312064
author Masopust, Jiří
Andrýs, Ctirad
Bažant, Jan
Vyšata, Oldřich
Kuca, Kamil
Vališ, Martin
author_facet Masopust, Jiří
Andrýs, Ctirad
Bažant, Jan
Vyšata, Oldřich
Kuca, Kamil
Vališ, Martin
author_sort Masopust, Jiří
collection PubMed
description BACKGROUND: Encephalitis with antibodies against N-methyl-D-aspartate receptor (NMDA-R) is classified as an autoimmune disorder with psychotic symptoms, which are frequently dominant. However, it remains unclear how frequently NMDA-R antibodies lead to a condition that mimics psychosis and first-episode schizophrenia. In our work, we investigated the presence of antibodies against NMDA-R in patients with first-episode psychosis (FEP) in comparison with healthy volunteers. METHODS: This study included 50 antipsychotic-naïve patients with FEP (including 21 women) and 50 healthy volunteers (including 21 women). The mean age of the patients was 27.4 (±7.4) years and that of the healthy controls was 27.0 (±7.3) years. Antibodies against NMDA-R in the serum were detected by immunofluorescence. RESULTS: None of the investigated patients with an FEP and none of the healthy controls showed positive antibodies against NMDA-Rs. CONCLUSION: According to results of studies, a small proportion of patients with an FEP possess antibodies against NMDA-R. However, the extent to which this finding contributes to the etiopathogenesis of the response to antipsychotic medication and whether immunomodulatory therapy is indicated in these cases remains uncertain.
format Online
Article
Text
id pubmed-4358648
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43586482015-04-01 Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia Masopust, Jiří Andrýs, Ctirad Bažant, Jan Vyšata, Oldřich Kuca, Kamil Vališ, Martin Neuropsychiatr Dis Treat Original Research BACKGROUND: Encephalitis with antibodies against N-methyl-D-aspartate receptor (NMDA-R) is classified as an autoimmune disorder with psychotic symptoms, which are frequently dominant. However, it remains unclear how frequently NMDA-R antibodies lead to a condition that mimics psychosis and first-episode schizophrenia. In our work, we investigated the presence of antibodies against NMDA-R in patients with first-episode psychosis (FEP) in comparison with healthy volunteers. METHODS: This study included 50 antipsychotic-naïve patients with FEP (including 21 women) and 50 healthy volunteers (including 21 women). The mean age of the patients was 27.4 (±7.4) years and that of the healthy controls was 27.0 (±7.3) years. Antibodies against NMDA-R in the serum were detected by immunofluorescence. RESULTS: None of the investigated patients with an FEP and none of the healthy controls showed positive antibodies against NMDA-Rs. CONCLUSION: According to results of studies, a small proportion of patients with an FEP possess antibodies against NMDA-R. However, the extent to which this finding contributes to the etiopathogenesis of the response to antipsychotic medication and whether immunomodulatory therapy is indicated in these cases remains uncertain. Dove Medical Press 2015-03-06 /pmc/articles/PMC4358648/ /pubmed/25834440 http://dx.doi.org/10.2147/NDT.S80746 Text en © 2015 Masopust et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Masopust, Jiří
Andrýs, Ctirad
Bažant, Jan
Vyšata, Oldřich
Kuca, Kamil
Vališ, Martin
Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia
title Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia
title_full Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia
title_fullStr Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia
title_full_unstemmed Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia
title_short Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia
title_sort anti-nmda receptor antibodies in patients with a first episode of schizophrenia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358648/
https://www.ncbi.nlm.nih.gov/pubmed/25834440
http://dx.doi.org/10.2147/NDT.S80746
work_keys_str_mv AT masopustjiri antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia
AT andrysctirad antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia
AT bazantjan antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia
AT vysataoldrich antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia
AT kucakamil antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia
AT valismartin antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia